Stockwinners Market Radar for June 04, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 174K shares of Intellia Therapeutics today

19:47 EDT GAP Airports reports preliminary May passenger traffic down 2.3% - Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for May 2024, compared with May 2023. For May 2024, the total number of terminal passengers at GAP's 12 Mexican airports decreased by 2.5%, compared to May 2023. Puerto Vallarta airport presented an increase in passenger traffic of 3.2%, while Tijuana, Guadalajara, and Los Cabos airports presented a decrease in passenger traffic of 5.2%, 2.7%, and 1.7% respectively, compared to May 2023. On the other hand, Montego Bay presented a decrease in passenger traffic of 0.3%.

18:05 EDT Abercrombie & Fitch CFO Lipesky sells 9,000 class A shares - In a regulatory filing, Abercrombie & Fitch EVP, COO and CFO Scott Lipesky disclosed the sale of 9,000 class A common shares of the company on May 31 at a price of $176.48 per share.

17:37 EDT Safety Shot announces strategic partnership with Mr. Checkout - Safety Shot "announced its strategic partnership with Mr. Checkout, a national network of independent distributors, full-line grocery distributors, and wagon-jobbers. This partnership marks a significant milestone in Safety Shot's mission to provide a revolutionary solution for responsible alcohol consumption to the masses. Mr. Checkout's extensive distribution network spans over 200,000 independent retail locations across the United States, offering Safety Shot an unparalleled opportunity to reach a broad audience of consumers. Mr. Checkout has a proven track record of successfully launching, scaling and promoting innovative products in the retail space as demonstrated by their work with partners such as 5-hour Energy and blu Electronic Cigarettes. With their support, Safety Shot aims to expand its footprint in convenience stores, neighborhood markets and independent grocers nationwide. Safety Shot is a first of its kind functional beverage crafted with Essential B vitamins, antioxidants, electrolytes, and nootropics designed to rapidly rehydrate, boost mental clarity, energy and overall mood. Disrupting the industry and creating a category of one, Safety Shot is the world's first beverage to reduce blood alcohol content by supporting its metabolism in as little as 30 minutes. This partnership with Mr. Checkout will help to introduce this revolutionary solution to consumers in varied retailers across the country."

17:26 EDT Stitch Fix sees Q4 advertising 9%-10% of revenue - Says making effort to increase client engagement. Says testing new promotional approach. Says continues to scale AI inventory tool. Says expects FY24 transportation costs will be lower than any year since FY20. Sees Q4 advertising 9%-10% of revenue. Says expects active clients to be lower quarter-over-quarter in Q4. Comments and guidance taken from Q3 earnings conference call.

16:59 EDT Chairman of Take-Two Zelnick sells $14M in company shares - Chairman of Take-Two Interactive Software, Strauss Zelnick, disclosed the sale of 87,561 shares of company stock at $159.49 per share on May 31 for a total transaction amount of $13,964,929.

16:33 EDT Personalis announces NeXT Personal test data at ASCO - The company states: "Personalis announced that data presented at the American Society for Clinical Oncology oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring. The NeXT Personal test is the first of a new class of ultra-sensitive liquid biopsy tests designed to detect the earliest traces of cancer recurrence and monitor a patient's response to therapy. The test can detect circulating tumor DNA down to an ultra-sensitive range and the data presented as ASCO highlights the clinical importance of this approach. Several hundred thousand cancer patients are put on immunotherapy treatment annually. While over 40% of patients with cancer are eligible for immunotherapy, only ~12% of patients respond, underscoring the need for a blood test that monitors treatment response for patients, doctors, and payers. An oral presentation showed the importance of NeXT Personal's use for immunotherapy monitoring. Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) presented data in an oral presentation that demonstrated that the baseline levels and the changes in levels of ctDNA detected by NeXT Personal are highly predictive of therapy response and clinical outcomes for late-stage cancer patients receiving immunotherapy. This includes the finding that patients who had a significant decrease in ctDNA levels from baseline to the third cycle of immunotherapy had overall survival that was more than two times longer than those who did not. They also demonstrated that NeXT Personal had an average lead time for detecting progression of 81 days over imaging."

16:32 EDT Weatherford signs MOU with QatarEnergy - Weatherford announced it has signed a memorandum of understanding, or MOU, with QatarEnergy to establish a framework aimed at advancing Tawteen's In-Country Value program objectives to develop the local energy industry. Per the MOU, the companies will collaborate to develop Qatari nationals and residents in technical fields, infrastructure, technology, and supply chains.

16:25 EDT Informatica launches new generative AI, Snowflake native app offerings - Informatica (INFA) announced at Snowflake's annual user conference, Snowflake Data Cloud Summit 2024, Native SQL ELT support for Snowflake Cortex AI Functions, the launch of Enterprise Data Integrator and Cloud Data Access Management for Snowflake (SNOW). These new offerings on the Snowflake AI Data Cloud will enable organizations to develop Generative AI applications, establish streamlined data integration and provide a centralized, policy-based access management, simplifying data governance and ensuring control over data usage. "We are excited to continue strengthening our ongoing collaborative relationship with Snowflake," said Pratik Parekh, SVP Product Development for Informatica. "At Snowflake Summit last year, we unveiled Informatica Superpipe for Snowflake, revolutionizing the industry with 3.5x faster data integration and replication. This year, we're continuing the momentum by unveiling our latest innovations, aimed at making it easier than ever for customers to access fast, secure and reliable data in Snowflake and leveraging the new Cortex AI features."

16:22 EDT Heart Test Laboratories regains compliance with Nasdaq listing requirements - Heart Test Laboratories, announced that on June 3 the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements and the scheduled hearing has now been cancelled.

16:21 EDT Cerence names Tony Rodriquez as interim CFO - Cerence announced that it has appointed Antonio Rodriquez as its interim Chief Financial Officer CFO , effective June 4 ... Mr. Rodriquez brings over 25 years of experience as a financial leader managing all aspects of finance and accounting for both public and private global companies, including in the eCommerce, SaaS, advertising media and consumer marketing industries. As Cerence's interim CFO, Mr. Rodriquez will lead the company's finance organization, including accounting, tax, FP&A, treasury, facilities, and procurement.

16:19 EDT Tela Bio appoints Jeffrey Blizard to its board of directors - TELA Bio (TELA) announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed (ABMD), a medical device technology company that operates as a stand-alone business within Johnson & Johnson's (JNJ)MedTech Segment, to its Board of Directors, effective June 4. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leadership and extensive experience will be a tremendous asset to our Board of Directors." "I am thrilled to join TELA Bio's Board of Directors during this dynamic period of growth," said Mr. Blizard. "I am confident that my broad range of sales expertise will significantly contribute to the TELA's continued success."

16:17 EDT Consolidated Water announces settlement of dispute with Mexico on CA project - Consolidated Water announced that on May 29 it settled the previously disclosed dispute between the Company's wholly-owned Dutch subsidiary, Consolidated Water Cooperatief and the United Mexican States relating to the termination by Mexican governmental authorities of a public-private partnership agreement under which CW-Cooperatief's indirect Mexican subsidiary Aguas de Rosarito, was to develop, build and operate a desalination plant and its accompanying pipelines in Playas de Rosarito, Baja California . Under the settlement agreement, CW-Cooperatief's Mexican subsidiary N.S.C. Agua, will sell the 20.1 hectares of land on which the Project's plant was to be constructed, including related rights of way and certain documentation owned by NSC relating to the Project for an aggregate price of MXN$616,144,000 or approximately $36,351,000.

16:10 EDT PagerDuty announces integration with Snowflake Trail - PagerDuty (PD) announced the integration of the PagerDuty Operations Cloud with Snowflake Trail, a rich set of observability capabilities unveiled today by Snowflake (SNOW), the AI Data Cloud company. By integrating the PagerDuty Operations Cloud with Snowflake Trail, joint customers can take a proactive approach to managing incidents that can deliver more resilient operations over time. Snowflake Trail is built with OpenTelemetry and open standards so developers can integrate with popular observability and alert platforms, including PagerDuty's comprehensive incident management platform. The combination of PagerDuty and Snowflake enables teams to quickly identify and resolve issues related to data infrastructure, data quality, AI operations and at the same time manage software costs. "A proactive approach to managing large amounts of data requires digital operations management including triaging and real-time communication of data operational issues," said Julia Fare, vice president of partnerships at PagerDuty. "Our expanded integration with Snowflake helps organizations enhance their data operations and further unlock the potential of their data infrastructures."

16:08 EDT HashiCorp and AWS in strategic pact to expand joint & go-to-market initiatives - HashiCorp (HCP) announced a strategic collaboration agreement with Amazon (AMZN) Web Services AWS to help customers implement infrastructure and security lifecycle management. Under this five-year agreement, AWS and HashiCorp will expand investments in co-innovation and go-to-market collaboration on behalf of customers."With Terraform Enterprise, I just click the button, and it does all the legwork for me," says Joe Brinkman, Engineering Manager, Cloud Operations at Earnin. Now, the Earnin cloud ops team can write Terraform configurations for Terraform Enterprise with just a few lines of code and provision workspaces in minutes, and it has visibility into all source code. As a result, provisioning and other operations processes are now 5 times faster, representing a 400 percent rate of acceleration. "AWS has been a critical partner to HashiCorp, and we're excited to expand our partnership and develop new customer solutions together," said Armon Dadgar, co-founder and CTO, HashiCorp. "This collaboration will enable us to support customers in managing the full lifecycle of cloud security and infrastructure to ensure efficient deployment on AWS." "As we continue our collaboration with HashiCorp, we're focused on delivering seamless, secure, and scalable cloud solutions to our customers," said Deepak Singh, VP of Compute Services, AWS. "This partnership underscores our commitment to innovation and customer success, leveraging the strengths of both AWS and HashiCorp to empower developers and businesses worldwide."

16:07 EDT Allison Transmission appoints Frederick Bohley as COO - Allison Transmission Holdings announced the appointment of G. Frederick Bohley III as the new COO, effective immediately. This appointment was approved by Allison's Board of Directors. Fred Bohley, who has been with Allison Transmission since 1991, will continue to hold his current roles as CFO and Treasurer while taking on his new responsibilities as COO. In his expanded role, Fred will oversee the Finance, Strategy and Business & Corporate Development, Information Systems & Services and Operations organizations. Fred Bohley, who has been with Allison Transmission since 1991, will continue to hold his current roles as CFO and Treasurer while taking on his new responsibilities as COO. In his expanded role, Fred will oversee the Finance, Strategy and Business & Corporate Development, Information Systems & Services and Operations organizations. The company has begun an extensive search for a new CFO to succeed Fred in these roles. In the interim, he will continue to serve in these capacities to ensure a smooth transition.

16:05 EDT Koru Medical announces new feasibility study - Koru Medical Systems announced a collaboration with a global pharmaceutical company to initiate a feasibility study with Koru Medical's Freedom Infusion System for an FDA and EMA approved subcutaneous oncology biologic drug, that is currently being delivered via a manual syringe administration by a healthcare professional. The Freedom System is a purely mechanical ambulatory drug delivery device with 11 drugs approved on the label and over 40,000 patients globally. The system is designed to deliver large volumes of biologic medications from 2mL to over 100mL subcutaneously. The Freedom System is capable of allowing patients to self-administer their therapy at home and/or by healthcare professionals in a clinic setting. Conversion of IV biologics to subcutaneous administration formulations is a growing trend in the oncology market. Evidence suggests subcutaneous administration of oncology therapy simplifies treatment, reduces pressure on hospitals, and improves patients' quality of life. With the development of new subcutaneous drug therapies, there is an opportunity to develop drug delivery administration solutions which will optimize drug administration for healthcare providers and patients. "This collaboration presents an exciting, new opportunity to enter the growing oncology subcutaneous biologic market to solve significant unmet needs in the delivery of this life-saving therapy with our patient-centric solutions," said Linda Tharby, KORU Medical's President and CEO. Linda Tharby went on to say, "There are multiple subcutaneous oncology biologics currently approved using manual administration with an estimate of over one million global infusions. Upon successful completion of the feasibility study, we anticipate progressing to commercialization of the Freedom System for this drug within the following 12 months."

15:40 EDT Avangrid signs PPA with CPS Energy for energy from Texas wind farm - Avangrid announced the signing of a power purchase agreement, or PPA, with CPS Energy for a 161-Megawatt, or MW, portion of Avangrid's Penascal I wind farm in Kenedy County, Texas south of Baffin Bay. This represents an extension and expansion of a previous 15-year agreement between the two companies for energy from Penascal I. CPS Energy more than doubled its power offtake from the project - increasing from 77 MW to 161 MW - and will now receive almost 80% of the power generated there. Avangrid is supplying CPS Energy with enough energy from Penascal I to power about 41,000 Texas homes.

15:11 EDT Axos Financial says short-seller report contains 'series of inaccuracies' - In a regulatory filing, Axos Financial stated: "A recently released report, by a self-described short-seller, made a series of misleading, incomplete, and false allegations centered on the quality of Axos' commercial real estate loan portfolio. This report contains a series of inaccuracies and innuendo that include false, incomplete and misleading allegedly factual information with respect to specific loans, incomplete or inaccurate descriptions of loan structures, failure to accurately describe the Axos lending counterparty, failure to mention guarantors or fund partners that provide significant support to the Axos credit position, as well as inaccurate discussions of loans that that have already been repaid but not represented in the report as having been repaid. We provided a detailed credit update on our last earnings call and there has not been any material change in credit performance as of today. As Axos disclosed in its investor presentation filed as Exhibit 99 to its Form 8-K filed with the Securities and Exchange Commission on May 7, 2024, its largest commercial real estate portfolio, CRE Specialty lending, with $5.22 billion dollars of outstanding balances as of March 31st, 2024 is a business that works almost exclusively through fund relationships, including many of the largest real estate funds in the world, such as Carlyle, the Related Group, Fortress Investment Group, Madison Realty Capital and others. When working with its fund partners, Axos structures the credits to take the most senior secured position in these loans. As a result of this structure, for Axos to lose any principal on these loans, the Axos fund partners would first have to lose the entire principal value of their position. In other words, the fund partners bear significant risk of loss from their investments prior to any risk of loss to Axos. This structure provides Axos strong collateral protection even in adverse market scenarios. As of March 31, 2024, the weighted average LTV of the Axos CRE Specialty Portfolio is 40%. The other large commercial real estate exposure is Multifamily mortgages. These mortgages are generally full warm-body recourse to the underlying borrower and originated at an average loan-to-value ratio of 55% as of March 31, 2024. The short-seller refers to loan repricing risk associated with this portfolio. A significant portion of the portfolio has already repriced with increased prepayment speed among loans that have repriced. Axos also provides lines of credit to its fund partners. These lines of credit are secured by multiple assets, have low advance rates, are cross-collateralized, and can, depending upon the circumstances, have direct recourse to the fund itself. Selecting any one asset on a multi-asset line of credit, as was done in this short-seller report, does not accurately portray the underlying risk of the facility. Additional data correcting some of the inaccuracies and misstatements in the report are provided below. The volume of inaccuracies and confidentiality obligations prevent addressing all of the inaccuracies, but a sufficient level of detail is provided to demonstrate that the report is not reliable." Reference Link

14:58 EDT Toll Brothers announces new community River Terrace coming to Tigard, Oregon - Toll Brothers announced its newest community, Toll Brothers at River Terrace, is coming soon to Tigard, Oregon. The community will feature two- and three-story luxury homes in the highly desirable Bull Mountain area. The first phase of the Spring Collection of homes is expected to open for sale this summer. Featuring seven different home designs in the first phase, Toll Brothers at River Terrace - Spring Collection offers modern open floor plans ranging from 2,724 to 4,248+ square feet with 4 to 6 bedrooms, 3 to 5 baths, and 2- or 3-car garages. Select floor plans offer the opportunity for luxury outdoor living, main-floor bedrooms, daylight basements, and versatile lofts and flex spaces. Pricing will start in the low $900,000s.

14:49 EDT Axos Financial trading halted, news pending

13:03 EDT Hookipa Pharma reports updated Phase 2 HB-200 combination data at ASCO 2024 - HOOKIPA Pharma announced updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive head and neck cancer. The updated data presented at the ASCO 2024 Annual Meeting is as of March 29 and includes 46 patients treated with HB-200 plus pembrolizumab in the first line setting. Results showed rapid and durable activation of antigen-specific CD8+ T cells and promising clinical activity. Among 35 evaluable patients data showed a 37 percent confirmed objective response rate 11 percent complete response rate, and 69% disease control rate, per RECIST 1.1 criteria. Duration of response was not yet mature with 62 percent of responders still on treatment as of the cutoff date. In a subset of 17 evaluable patients with CPS of 20 or higher, the updated data showed a 53 percent confirmed ORR, 18 percent CR rate, and 82 percent DCR. These patients are representative of the company's planned pivotal Phase 2/3 trial population, which is targeted to begin enrolling patients in the fourth quarter of 2024. Additionally, preliminary PFS for the CPS 20 or higher subgroup was 16.3 months and is encouraging based on the historical PFS data of 3.4 months reported for pembrolizumab alone. The preliminary OS rate was 88% at 9 months, and median OS was unreached as of the cutoff date with 16 of 19 patients still alive. Median follow-up for these patients was 8.4 months. "Based on the evidence from the Phase 2 trial of HB-200 plus pembrolizumab, I am encouraged by the potential this immunotherapy combination may provide as a targeted therapeutic option for HPV16+ head and neck cancer patients," said Dr. Alan Ho, Head and Neck Oncologist at Memorial Sloan Kettering Cancer Center and a trial investigator. "The data show that this combination has been generally well-tolerated and can likely increase immunogenic tumor cell death, leading to improved response rates and potential durability."

12:04 EDT Bath & Body Works falls -14.3% - Bath & Body Works is down -14.3%, or -$7.39 to $44.42.

12:02 EDT Designer Brands falls -22.3% - Designer Brands is down -22.3%, or -$2.46 to $8.59.

12:00 EDT ADC Therapeutics rises 15.4% - ADC Therapeutics is up 15.4%, or 51c to $3.82.

11:50 EDT Pono Capital Two Inc trading resumes

11:45 EDT Pono Capital Two Inc trading halted, volatility trading pause

11:20 EDT CRYO-CELL International, Inc. trading halted, volatility trading pause

11:10 EDT Cisco announces launch of Nexus HyperFabric AI cluster solution - Cisco (CSCO) announced what it says is "a breakthrough AI cluster solution" with Nvidia (NVDA) for the data center that "transforms how customers build, manage and optimize infrastructure and software." The company stated: "Cisco is bringing to market a new enterprise-ready, end-to-end infrastructure solution to scale generative AI workloads. The Cisco Nexus HyperFabric AI cluster solution combines Cisco AI-native networking with NVIDIA accelerated computing and AI software, and a robust VAST data store. It is designed to enable customers to focus on AI-driven innovation and new revenue opportunities rather than IT management." Select customers may have early trial access to this AI solution in Q4 of CY 2024, with general availability expected shortly thereafter, Cisco added. Reference Link

10:23 EDT Green Thumb says 'policy is not to comment on market rumors' - Green Thumb Industries (GTBIF) responded to media speculation regarding the possibility of a transaction involving the company. "The company's policy is not to comment on market rumors," Green Thumb stated in a press release after The Wall Street Journal's Lauren Thomas reported that Green Thumb's' Chief Executive Ben Kovler sent a letter to Boston Beer (SAM) founder and Chairman Jim Koch on Sunday seeking to discuss a potential combination.

10:06 EDT Warner Bros. Discovery's Max announces price increase - Effective today, Tuesday, June 4, the cost of certain Max monthly and yearly plans will increase, Warner Bros. Discovery announced. The monthly Ad-Free plan will increase by $1 per month, making the new price $16.99/month. The yearly Ad-Free plan will increase by $20 per year, making it $169.99/year. The monthly Ultimate Ad-Free plan will increase $1 per month, making the new price $20.99/month. The yearly Ultimate Ad-Free plan will increase by $10 per year, making it $209.99/year. "These prices are effective immediately for new subscriptions. The Max With Ads plan remains unchanged at $9.99/month or $99.99/year. Existing subscribers will be notified 30 days in advance of their plan renewing and see price increases starting from their next billing cycle on or after Thursday, July 4, 2024. Current yearly subscribers will not see an increase until renewal," Warner Bros. Discovery stated.

10:05 EDT Axos Financial falls -12.5% - Axos Financial is down -12.5%, or -$6.56 to $45.90.

10:03 EDT Designer Brands falls -16.7% - Designer Brands is down -16.7%, or -$1.84 to $9.21.

10:01 EDT XPO, Inc rises 6.2% - XPO, Inc is up 6.2%, or $6.36 to $108.73.

09:52 EDT Logistic Properties of The Americas trading resumes

09:51 EDT Ault Disruptive Technologies Corp trading resumes

09:50 EDT SINTX Technologies Inc trading resumes

09:49 EDT XPO, Inc rises 6.0% - XPO, Inc is up 6.0%, or $6.12 to $108.49.

09:47 EDT Li-Cycle rises 634.6% - Li-Cycle is up 634.6%, or $3.03 to $3.51.

09:41 EDT Ault Disruptive Technologies Corp trading halted, volatility trading pause

09:40 EDT Montana Technologies Corp trading resumes

09:35 EDT Montana Technologies Corp trading halted, volatility trading pause

09:34 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:30 EDT Lavoro Ltd trading halted, volatility trading pause

09:23 EDT Concentrix debuts on Fortune 500 list - Concentrix Corporation announces its debut on the Fortune 500 list, securing the 499th position. This milestone marks a significant achievement in Concentrix' history, reflecting its sustained growth and commitment to delivering transformative solutions that power the world's best brands today and into the future. "We are incredibly proud to be joining the Fortune 500. It is not only a testament to our game-changers' hard work and dedication but also a clear indicator of our position as a leading technology and services company that designs, builds, and runs fully integrated, end-to-end solutions across the entire enterprise, at speed and scale," said Chris Caldwell, President and CEO of Concentrix. "This achievement motivates us to continue to deliver outcomes unimagined for our 2000+ clients and their customers by investing in emerging technology and pushing the boundaries of innovation."

09:22 EDT Medallion announces Glass Lewis recommends vote 'FOR' director nominees - Medallion Financial announced that independent proxy advisory firm Glass, Lewis & Co. has recommended that Medallion shareholders vote on the BLUE proxy card "FOR" ONLY the candidates nominated by the Board of Directors, Robert M. Meyer and David L. Rudnick and "FOR" the advisory vote on the compensation of the Company's named executive officers in connection with the Company's 2024 Annual Meeting of Shareholders. In its June 3, 2024, report, Glass Lewis commented: "Financially, it appears to us that the Company's overall performance, as measured by TSR and other metrics detailed above, has been in line with or better than its peers ...On review of certain operating metrics of the Company as a whole, as well as of its consumer lending business lines, which represent a major part of the Company's revenues in the past years, we believe the Company's performance was largely in line with or better than its peers.... we believe it may be reasonable for shareholders to afford the current board with discretion and flexibility to execute on the Company's current strategy at this time....we believe the board has highlighted valid potential concerns regarding the independence of the Dissident Nominees given their current employment with a significant debtholder and an industry competitor."

09:21 EDT Verisk's NER, KYCS Global collaborate to enhance heavy equipment security - National Equipment Register, NER, a Verisk business, and KYCS Global, announced that they are collaborating to provide cutting-edge security and recovery solutions for heavy equipment assets. This strategic integration revolutionizes the ecosystem for theft-recovery and security of assets and offers unprecedented benefits to businesses across agriculture, construction, and industrial services industries. The agreement between Verisk, a leading global data analytics and technology provider, and KYCS Global will combine KYCS's recovery device technology with NER's robust data and tracking capabilities. It will also bring together related incentives from insurance providers and will be available to equipment and fleet operators across North America. As a result of this enhancement, NER's IRONwatch solution will now be called IRONwatch Locate, to better communicate the increased functionality offered to clients.

09:19 EDT Motorsport Games unveils June updates for Le Mans Ultimate, 2024 content - Motorsport Games is announcing a significant update to Le Mans Ultimate, the official game of the FIA World Endurance Championship and 24 Hours of Le Mans. As part of the upcoming June update, players can look forward to new gameplay features, including a Radar, Replay Suite and improved Race Starts, all of which were highly requested by the community. The June update, scheduled for release on June 10th, will also introduce the BMW M Hybrid V8 LMDh as the first free item of DLC, celebrating BMW's 25th anniversary of its first outright win at Le Mans. Additionally, an array of new 2024 Hypercar liveries for existing cars will also be available free of charge, giving more options on paint scheme to the game's fans.

09:18 EDT Ford reports May U.S. sales up 11.2% to 190,014 vehicles - Ford reports May U.S. Electric Vehicle sales of 8,966, up 64.7% year-over-year, Hybrid Vehicle sales of 17,631, up 64.5%, and Internal Combustion sales of 163,417, up 5.6%, for total vehicle sales of 190,014 units, up 11.2% compared to the same month of last year. Reference Link

09:17 EDT Tiziana Life Sciences submits grant application to ALS Association - Tiziana Life Sciences announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the Neurological Clinical Research Institute at Mass General Hospital, a founding member of Mass General Brigham. The grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which is specifically designated to support a groundbreaking clinical trial.

09:16 EDT YY Group appoints three new members to board of directors - YY Group Holding announces the appointment of three new members to its Board of Directors: Chan Yong Xian, Cheong Hai Poh, and Lai Wai Kit.

09:15 EDT Philips announces next-gen AI-enabled cardiovascular ultrasound platform - Royal Philips announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs. Integrated into the company's EPIQ CVx and Affiniti CVx ultrasound systems, the new FDA 510(k) cleared AI applications significantly advance Philips' cardiovascular imaging and diagnosis solutions, automating measurements and speeding workflows to increase productivity

09:12 EDT Freight Technologies announces major expansion of Fr8Radar Module in Fr8App - Freight Technologies announces a significant milestone in the expansion of its Fr8Radar module within the Fr8App platform. In the first half of 2024, Fr8Radar has successfully integrated with 15 new GPS providers, bringing the total number of GPS integrations to 28. This advancement brings Fr8App closer to its goal of becoming the most connected, comprehensive, and integrated platform for monitoring trucks in Mexico and facilitating cross-border logistics.

09:10 EDT Cipher Mining produced 166 bitcoin in May - In May, while the bitcoin mining industry experienced the first full month of impact from the most recent halving, Cipher continued to deliver positive cash flows while building its bitcoin inventory and executing the expansion of its Bear and Chief sites. Also, Cipher's power provider at its Odessa data center has used a significant amount of its annual curtailment budget year-to-date, in advance of the four summer months that typically feature peak demand in Texas. Given the hot weather forecast for the summer, and Cipher's unique ability to re-sell power secured under contract at a low fixed price, the company expects to be well-positioned to benefit if high market prices materialize this summer. Cipher sold 50 BTC in May.

09:09 EDT SentinelOne and Advantage team on MDR services - The future of managed detection and response will be driven by generative artificial intelligence, and SentinelOne and Advantage, the trusted and leading New Zealand managed service, networking and security provider, are joining forces to deliver it to enterprises... The long-time partners announced that Advantage will integrate SentinelOne's PurpleAI, the industry's leading AI security analyst, into its cutting-edge managed detection and response MDR service, empowering organizations of all sizes to defend against AI-driven attacks with AI-driven solutions. "Many vendors are talking about generative AI, but SentinelOne is actually delivering it with technology that is transforming the way security operations work," said Brad Pearpoint, Managing Director, Advantage. "Together, with our managed service offerings, we can make top-tier Security Operations Centers SOC a reality for every business."

09:06 EDT Oblong announces letter of intent to merge with Dwellwell Analytics - Oblong announced that it has signed a non-binding letter of intent with Dwellwell Analytics to acquire 100% of the outstanding equity interests of Dwellwell .Pursuant to the terms of the Letter of Intent, Dwellwell securityholders would, after giving effect to the proposed Merger, own 67% of the equity of the combined company and equity holders of Oblong would own 33% of the equity of the combined company, on a fully diluted basis..."After undertaking a comprehensive process to explore and evaluate a range of strategic options, our Board and Management team believe this transaction with Dwellwell is the best strategic alternative for Oblong and represents an opportunity to create substantial value for our shareholders," said Pete Holst, Oblong CEO. Both parties are currently completing their respective due diligence reviews and are continuing to negotiate the terms of a Definitive Merger Agreement. Accordingly, Oblong cannot provide any assurance that it and Dwellwell will successfully negotiate and enter into a Definitive Merger Agreement or that it will effect the Merger with Dwellwell or, even if it is able to consummate such a Merger, that the terms of any such Merger will be on the terms set forth in the Letter of Intent. The Merger would be subject to board and shareholder approval, regulatory approval, each party satisfying a net cash closing condition and other customary closing conditions...

09:03 EDT XTI Aerospace signs letter of intent with AVX Aircraft Company - XTI Aerospace announced that its subsidiary, XTI Aircraft Company, has signed a Letter of Intent with AVX Aircraft Company to provide development, design, and certification services to support XTI Aircraft's proprietary and patented TriFan 600, a fixed-wing aircraft with vertical takeoff and landing capability. The definitive agreements are expected to be signed in the coming weeks. Under the proposed terms of the definitive agreement, XTI Aircraft, led by XTI Aerospace Senior Vice President of Business and Program Development Don Purdy, will provide management, direction, and oversight of the TriFan 600 program. AVX will become the prime contractor including detailed design, program management, subcontract management and certification support services.

09:01 EDT Arthur J. Gallagher acquires Crawford Insurance - Arthur J. Gallagher acquired Pittsburgh, Pennsylvania-based Crawford Insurance. Terms of the transaction were not disclosed. Crawford Insurance is a retail insurance agency offering property/casualty products to commercial and personal lines clients in Pennsylvania, South Carolina and Virginia. James Crawford and his team will remain in their current location under the direction of Sean Gallagher, head of Gallagher's Great Lakes region retail property/casualty brokerage operations.

08:49 EDT Predictive Oncology launches novel 3D cell technology - Predictive Oncology announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. Organ specific 3D cell cultures more closely mimic human tissue architecture than do traditional 2D assays and provide a more representative method for in vivo drug candidate clinical testing. This allows for the more robust predictions of clinical outcomes and can be used to optimize candidate selection for subsequent clinical development. "The results of our studies demonstrate the importance of incorporating more complex 3D cell applications into the global drug discovery and development processes, to decrease the time to market and cost of new drugs, while reducing the need for animal testing and time-consuming iterations during clinical trials," said Raymond Vennare, Chief Executive Officer of Predictive Oncology.

08:47 EDT Surrozen initiates dosing of first patient in Phase 1b trial of SZN-043 - Surrozen announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis. The Phase 1b is an open-label, multi-center clinical trial that will enroll approximately 30 patients with severe alcohol-associated hepatitis. The Company plans to evaluate safety, pharmacokinetics, immunogenicity and a number of efficacy endpoints including changes in MELD score, changes in Lille score and overall survival. The MELD and Lille scores have been shown to correlate with clinical improvement and 90-day survival. "We are excited to begin enrollment in our Phase 1b clinical trial with our lead product candidate, SZN-043. The R&D organization has worked diligently to finalize regulatory approvals in multiple countries, initiate study sites and begin dosing of the first patient on schedule," said Craig Parker, President and Chief Executive Officer of Surrozen. "We are gaining momentum in our SZN-043 clinical trial program in severe alcohol-associated hepatitis and anticipate that proof-of-concept data may be available in the first half of 2025."

08:46 EDT Artelo Biosciences presents important new data on ART26.12 - Artelo Biosciences announced that Professor Saoirse O'Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference is being held from June 4-6, 2024, in Nottingham, UK. The presentations, titled, "ART26.12, a Novel Fatty Acid-binding Protein 5 Inhibitor, shows Efficacy in Breast Cancer-Induced Bone Pain" and "The Effects of the Fatty Acid Binding Protein 5 Inhibitor ART26.12 in a Rat Model of Diabetic Neuropathy," highlight Artelo's Fatty Acid Binding Protein 5 inhibitor under development for painful peripheral neuropathies and various cancers. Specifically, effective doses and plasma exposures are consistent with previously published data of ART26.12 in oxaliplatin-induced peripheral neuropathy. ART26.12 represents a significant advancement in the Company's commitment to developing innovative therapies targeting lipid signaling pathways.

08:44 EDT Nano Nuclear appoints Fratoni as Senior Director, Head of Reactor Desgn - NANO Nuclear Energy announced that Massimiliano Fratoni, Ph.D., a Xenel Distinguished Professor and Chair in the Department of Nuclear Engineering at the University of California, Berkeley, has been appointed as NANO Nuclear's Senior Director and Head of Reactor Design.

08:42 EDT Safe & Green announces expanded contract with a government contractor - Safe & Green Holdings announces it has received an expanded contract, valued in excess of $1M, to construct an additional 11 container modules and related services for a government contractor to be used by a major U.S. government agency. Paul Galvin, Chairperson and CEO of Safe and Green Holdings stated, "We are thrilled to announce a further expansion of our agreement with a leading government contractor, illustrating the quality of our work, ability to meet the customer's exacting standards, and our commitment to supporting the U.S. military. This brings the total container modules ordered and delivered for this undisclosed military-related agency to 26 units, and we look forward to further expanding our relationship with this premier contractor."

08:41 EDT Barrett Business declares four-for-one stock split - Barrett Business Services announced that its board of directors has declared a four-for-one split of the Company's common stock in the form of a stock dividend. Each stockholder of record on June 14, 2024, will receive a dividend of three additional shares of common stock for each share they hold, to be distributed on June 21, 2024. Trading will resume on a stock split-adjusted basis on June 24, 2024. The stock split is expected to improve the overall trading efficiency of BBSI's stock and make stock ownership more accessible to a broader range of investors.

08:40 EDT Lincoln Educational will deliver workforce training to CMC technicians - Lincoln Educational Services has entered into a workforce development partnership with Container Maintenance Corporation, CMC. Training begins in June at CMC's main branch in Charleston, SC. The five-year agreement pairs one of America's premier career training schools with a leader in the $50 billion North American intermodal freight transportation industry*. Specially selected Lincoln Tech instructors will be tasked with delivering the instruction to members of CMC's existing workforce.

08:39 EDT Gilead reached agreement in principle to resolve federal TDF litigation - Gilead Sciences has reached an agreement in principle with counsel representing the overwhelming majority of plaintiffs in the federal TDF litigation pending in the U.S. District Court for the Northern District of California, the company announced. "Gilead entered into this agreement to avoid the cost and distraction of litigating these cases, and in no way is this settlement an admission of liability or wrongdoing. In general terms, the agreement provides that Gilead will make a one-time payment of up to $40M to the group of eligible plaintiffs (approximately 2,625 plaintiffs). The agreement is subject to certain conditions, including that at least 98% of these eligible plaintiffs elect to participate in the settlement. Gilead expects that the settlement will resolve the claims of the overwhelming majority of plaintiffs in the federal TDF litigation. However, there may be some plaintiffs in the federal TDF litigation who do not elect to participate in the settlement and there are others who are not part of this agreement. As to those plaintiffs, Gilead will continue to vigorously defend itself. Gilead has never stopped working to improve the lives of people with HIV. The evidence shows that the long-term safety of TAF was unknown and impossible to predict in October 2004 when Gilead stopped TAF development in favor of further developing TDF medications. Today, both TDF- and TAF-containing medicines are approved by the FDA, are recommended in the U.S. Department of Health & Human Services HIV treatment guidelines, and successfully help treat and prevent HIV in millions of people. This agreement in the federal TDF litigation does not affect the California state TDF litigation that is currently pending in the California Supreme Court. Last month, the California Supreme Court granted Gilead's petition to review the Court of Appeal's decision. Briefing in the California Supreme Court will begin in July, with Gilead's initial brief due on July 15," Gilead stated. Reference Link

08:36 EDT Bath & Body Works sees FY24 free cash flow $675M-$775M - Bath & Body expects to continue its annual dividend of 80c per share, with intention to increase with sustained earnings growth, the company said, adding that it expects to repurchase approximately $300M of shares opportunistically throughout fiscal 2024. B&BW will continue to consider opportunistic debt repurchases, it said. Comments taken from Q1 earnings conference call presentation slides.

08:33 EDT AbbVie: Rinvoq available in U.S. for patients two and older with pJIA, PsA - AbbVie announced that Rinvoq is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis as well as psoriatic arthritis, provided they have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Additionally, a new weight-based oral solution, Rinvoq LQ, is now available as an option for these pediatric populations.

08:22 EDT Axos Financial down 18% after Hindenburg publishes short report - Shares of Axos are down $9.51, or 18%, to $42.95 in pre-market trading.

08:18 EDT Kandi Technologies debuts enhanced 10K high-clearance electric UTV - Kandi Technologies Group announced the launch of its newly developed 10K high-clearance, fully electric UTV, a sophisticated upgrade designed to elevate the off-road experience. This model builds upon the chassis of the acclaimed 10K model, integrating an extended swing arm and a widened wheelbase for unmatched stability in a variety of settings. The vehicle features extended airbag shock absorbers, which significantly raise the ground clearance and enhances its traversability, whether navigating potholed roads or traversing wet, muddy landscapes.

08:17 EDT TeraWulf self-mined 186 bitcoin in May - TeraWulf provided an unaudited monthly production and operations update for May 2024. May 2024 Production and Operations Highlights: Self-Mined Bitcoin: Mined 186 bitcoin in May, reflecting the first full month of reduced block rewards following the April Halving event, with an average production rate of approximately 6.0 bitcoin per day. Power cost: Averaged $31,239 per bitcoin self-mined in May, reflecting an approximate rate of $0.039/kWh and excluding the benefit of expected demand response or ancillary services proceeds. Operating Capacity: TeraWulf's installed and operational self-mining capacity reached approximately 8.0 EH/s, representing an 82% year-over-year increase. AI/HPC Pilot: Advancing 2.0 MW AI pilot at Lake Mariner, designed to accommodate next generation GPU technology and meet SOC 2 standards.

08:15 EDT Mobile X to supply high-performance connectors Navy's Standard Missile-6 program - Mobix Labs announces a milestone achievement in collaboration with the U.S. defense sector. Mobix Labs has been selected as a supplier of connectors to be used in the Navy's Standard Missile-6 program and has completed its initial product delivery. The Standard Missile-6 is an integral component of the U.S. Navy's defense arsenal, and the only weapon that can perform anti-air warfare, anti-surface warfare and ballistic missile defense and sea-based missions. Its deployment enhances America's naval fleet ability to defend against threats, ranging from enemy aircraft to ballistic missiles.

08:13 EDT Occidental, BHE Renewables form joint venture - Occidental (OXY) and BHE Renewables, a wholly owned subsidiary of Berkshire Hathaway Energy (BRK.A), announced they formed a joint venture for the demonstration and deployment of TerraLithium's Direct Lithium Extraction, DLE, and associated technologies to extract and commercially produce high-purity lithium compounds from geothermal brine. TerraLithium, a wholly owned subsidiary of Occidental, has patented DLE technologies that have the potential to process any lithium-containing brine into a responsibly sourced supply of high-purity lithium. BHE Renewables operates 10 geothermal power plants in California's Imperial Valley, which process 50,000 gallons of lithium-rich brine per minute to produce 345 megawatts of clean energy. The joint venture has begun a project at BHE Renewables' Imperial Valley geothermal facility to demonstrate the feasibility of using the TerraLithium DLE technology to produce lithium in an environmentally safe manner.

08:11 EDT Locafy announces first signed contracts through agreement with diDNA - Locafy Limited announced that it had signed the Company's first contracts through its partnership with diDNA, a leading AdTech provider for the publisher ecosystem. The two contracts, with one U.S.-based and one Australian-based media publisher, will see Locafy implement its Article Accelerator technology to deploy a standalone paid article solution to the main publisher website. Through Locafy's recently announced value-based pricing model, Locafy stands to earn a percentage of advertising revenue generated through the publishers' websites in addition to services fees associated with onboarding and maintenance once the solution is deployed by Locafy's site builder. "We believe that these contracts are just the beginning of the opportunity for Locafy through our partnership with diDNA," said Locafy CEO Gavin Burnett. "Recent search engine algorithm updates have caused dramatic website traffic losses throughout the online publishing industry, and, in some cases, a loss in substantial revenue related to paid content."

08:09 EDT Charles River announces launch of VCG initiative with Sanofi - Charles River Laboratories (CRL) International announced the launch of its Virtual Control Groups VCG initiative with Sanofi (SNY). The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets. The VCG collaboration is a project guided by Charles River's Alternative Methods Advancement Project AMAP , an initiative focused on reducing the use of animals in research. "Charles River is uniquely positioned to combine the science of toxicology with the power of machine learning to drive greater use of VCGs for nonclinical research across the industry," said Shannon Parisotto, Corporate Executive Vice President, Global Discovery & Safety Assessment, Charles River. "We have an unmatched breadth of data, providing a powerful database of study parameters. By leveraging this historical information, we are able to reduce control group animals and provide clients with meaningful study results."

08:06 EDT Equillium announces data from EQ101 study - Equillium announced topline data from its Phase 2, single dose, proof-of-concept, or PoC, study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata, or AA, an autoimmune disease driven by an immune cell attack of the hair follicles that causes hair loss. The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as signs of efficacy using Severity of Alopecia Tool, or SALT, scores, where a score of 100 represents total scalp hair loss and a score of 0 represents no scalp hair loss. Results from the study demonstrated a favorable safety and tolerability profile with no serious adverse events, or SAEs, and improvements in SALT scores above the published historically low placebo response rates. Of all subjects that completed 24 weeks of treatment, 20% achieved a SALT score of less than or equal to 20 by week 24. Of those subjects with moderate to severe AA at baseline that completed 24 weeks of treatment, 29% achieved a SALT score of less than or equal to 20 by week 24, and a mean SALT improvement from baseline of 18%. Throughout 24 weeks of treatment and 4 weeks of follow up, EQ101 was well tolerated with no SAEs and no notable changes in safety laboratory, electrocardiogram, vital signs, or physical exam findings were reported. The majority of adverse events were Grade 1 or 2, with the most common being upper respiratory tract infection, headache and fatigue. The two Grade 3 events in two subjects considered related to study treatment were a case of transient lymphocytopenia and fatigue.

08:06 EDT Bristol Myers: Opdivo+Yervoy improved OS vs Lenvatinib or Sorafenib in HCC - Bristol Myers Squibb announced the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo or nivolumab plus Yervoyor ipilimumab, compared to investigator's choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma HCC . Results from the study will be featured in a late-breaking oral presentation at the 2024 ASCO Annual Meeting today, June 4. "Despite recent advances in the treatment of HCC, prognosis remains poor for patients with advanced HCC, and therapies that improve survival and help delay disease progression are needed," said Peter R. Galle, M.D., of the University Medical Center, Mainz. "These data from CheckMate -9DW confirm the efficacy of the combination of nivolumab and ipilimumab and ability to extend survival, which is very encouraging." "The combination of Opdivo plus Yervoy has been an established second-line treatment for patients with advanced HCC and, with these results, we can demonstrate that Opdivo plus Yervoy significantly increases survival and other key efficacy measures in the first-line setting for patients with advanced disease," said Dana Walker, M.D., M.S.C.E., vice president, global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb. "We look forward to discussing these data with health authorities and potentially bringing the dual immunotherapy combination of Opdivo plus Yervoy to more patients."

08:04 EDT Vtex partners with Pinterest for social commerce expansion - Vtex (VTEX) is announcing its partnership with Pinterest (PINS) to help consumer brands broaden their social commerce footprint and connect with more customers. Through its commerce platform, VTEX's 2,600 global customers can reach and engage on Pinterest. The collaboration enables customers to integrate their product catalogs, create Pins, and run performant shopping campaigns on Pinterest.

08:04 EDT Soleno Therapeutics set to join Russell 3000 Index - Soleno Therapeutics announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

08:04 EDT Regulus poised to be added to Russell 3000, Russell 2000 indexes - Regulus Therapeutics announced that it expects to be added to the broad-market Russell 3000 Index and the Russell 2000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

08:03 EDT Ashland appoints Faccin as SVP, General Manager - Ashland (ASH) announced that Alessandra Faccin will join the company as senior vice president and general manager, Life Sciences, effective June 10, 2024. Faccin will report to Guillermo Novo, chair and chief executive officer, Ashland. Most recently Faccin was president of Sealed Air Corporation (SEE), Asia Pacific.

08:02 EDT Broadridge announces CFO transition - Broadridge CFO Edmund Reese will be stepping down from his role effective June 30, to become CFO of Aon. Ashima Ghei, who is currently the CFO of Broadridge's $4.5B revenue Investor Communication Solutions segment, will serve as Interim CFO. Broadridge has initiated a search process for a permanent successor that will include both internal and external candidates. Reese has served as Broadridge's CFO since 2020. Ghei has served as the CFO of Broadridge's Investor Communication Solutions segment since January 2022 and is a member of the company's Executive Leadership Team. Prior to joining Broadridge, Ghei spent 18 years at American Express.

07:59 EDT Core Scientific signs 12-year contracts with CoreWeave - Core Scientific announced the signing of a series of 12-year contracts with CoreWeave, the AI Hyperscaler. Under the terms of the agreements, Core Scientific will deliver approximately 200 megawatts, or MW, of infrastructure to host CoreWeave's high-performance compute, or HPC, operations. Core Scientific will modify multiple existing, owned sites to host CoreWeave's Nvidia GPUs. The site modifications are expected to commence early in the second half of 2024 and achieve operational status in the first half of 2025. Per the agreements, all capital investments required to modify Core Scientific's existing infrastructure into application-specific data centers customized for dense HPC will be funded by CoreWeave. An estimated $300M of the capital investments associated with Core Scientific-owned infrastructure will be credited against hosting payments at no more than 50% of monthly fees until fully repaid. The agreements with CoreWeave provide opportunities for two renewal terms of five years each. The agreements also provide optionality for further expansion with meaningful additional megawatts at other Core Scientific sites, potentially ranking Core Scientific as one of the largest data center operators in the United States. Once the approximately 200 MW of HPC infrastructure is operational, the project is estimated to generate total cumulative revenue for Core Scientific of over $3.5B during the initial 12-year terms of the contracts. Estimated average annual revenue from the contracts is expected to be approximately $290M. From revenue to gross margin, this is expected to enhance earnings power and drive shareholder value. In connection with this expansion of Core Scientific's HPC hosting strategy, Core Scientific intends to redeploy certain of its bitcoin mining capacity from designated HPC sites to other of its dedicated bitcoin mining sites to support business continuity and growth.

07:47 EDT Jacobs selected to design critical freight corridor in Washington State - Jacobs was selected by the Washington State Department of Transportation as lead designer for the SR 509 Stage 2 Completion Project. This project, part of the Puget Sound Gateway Program, will complete a part of the state's transportation network between I-5 and SR 509, creating links between the Port of Seattle and manufacturing and distribution centers in the Kent Valley, ending near Sea-Tac Airport. As lead designer, Jacobs is part of the design-build team led by Guy F. Atkinson Construction that will design and construct this critical project, including five new bridges and one bridge modification; stormwater conveyance and treatment facilities; and construction of active transportation infrastructure that supports walking, cycling and other physical modes of travel.

07:36 EDT Frontdoor to acquire 2-10 Home Buyers Warranty for $585M in cash - Frontdoor announced it has entered into an agreement to acquire 2-10 Home Buyers Warranty or 2-10 HBW, in an all cash transaction valued at $585 M. The transaction is anticipated to close in the fourth quarter of 2024, subject to regulatory approval and other customary closing conditions. "We are extremely excited about the 2-10 acquisition. I am optimistic that it will be a tremendous growth catalyst for our business and will help improve the trajectory of our customer base, revenue and earnings," said Frontdoor. Chairman and CEO Bill Cobb. "Additionally, we will be able to diversify and expand into the new home segment, which will open up cross-selling opportunities for home warranties and our on-demand services. In short, through this acquisition, we will gain a highly complementary business that aligns very well with our strategic growth priorities." ...The combined company's strengthened financial profile is expected to be additive to Adjusted EBITDA and free cash flow generation in 2025, the first anticipated full year of ownership by FrontdoorThe transaction is valued at $585M in cash, on a cash-free, debt-free basis , and is supported by a fully committed bridge facility and cash. Permanent financing is expected to consist primarily of new debt. The transaction is anticipated to close in the fourth quarter of 2024, and is subject to customary closing conditions, including required regulatory approvals. The transaction has been unanimously approved by the Board of Directors of Frontdoor...

07:33 EDT CME Group reports record May ADV of 26M contracts - CME Group reported its May 2024 market statistics set a new average daily volume - ADV - record of 26 million contracts for the month, up 4% from May 2023. The company's interest rate and metals products also reached May ADV records, as its deeply liquid U.S. Treasury complex hit a new single-day record of 34,350,339 contracts on May 28. Additional May 2024 product highlights compared to May 2023 include: interest rate ADV increased 3%, energy ADV increased 22%, agricultural ADV increased 9%, metals ADV increased 33%, international ADV increased 12% to 7.5 million contracts, with EMEA ADV up 17% and Latin America up 10%.

07:23 EDT Allegion acquires Krieger Specialty Products, terms undisclosed - Allegion has acquired Krieger Specialty Products. Based in the Los Angeles, California, area, Krieger is a U.S. manufacturer of high-performance special purpose doors and windows for industrial, commercial and institutional markets. Krieger's solutions include security, radio frequency, acoustical, forced entry, bullet, blast and thermal applications, and they're installed in a wide range of facilities ranging from data centers, hospitals, power plants and government offices to broadcasting stations, theaters, museums and banks. Krieger will operate as part of the Allegion Americas segment, led by Allegion Senior Vice President Dave Ilardi. Terms of the transaction were not disclosed.

07:13 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units covering an aggregate of 39,050 shares, of BioCryst common stock. The options and RSUs were granted as of May 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

07:12 EDT Annexon announces Phase 3 trial on ANX005 met primary endpoint - Annexon announced positive topline results from its randomized placebo-controlled pivotal Phase 3 trial in patients with Guillain-Barre syndrome, GBS. The Phase 3 trial met its primary endpoint, with ANX005 30 mg/kg achieving a highly statistically significant 2.4-fold improvement on the GBS-disability scale, GBS-DS, at week 8. ANX005 30 mg/kg treatment also demonstrated improvements versus placebo on key secondary endpoints, including early gains in muscle strength by Medical Research Council sum score at day 8 and at week 8, and a median of 28 fewer days on artificial ventilation through week 26. Additionally, ANX005 30 mg/kg demonstrated a 31-day reduction in the median time to walk independently versus placebo in a prespecified analysis. ANX005 30 mg/kg treated patients got better sooner on each of these assessments, presenting important clinical care outcomes for patients and the healthcare community. ANX005 also provided an early reduction in the prespecified analysis of serum levels of neurofilament light chain, a biomarker of nerve damage.

07:10 EDT 5E Advanced Metals announces resignation of CEO Brennan, Weibel to succeed - 5E Advanced Materials provided a business update regarding its executive leadership and organizational structure. Effective June 3, 2024, the Company announces the resignation of Chief Executive Officer Susan Brennan. The Company's Board of Directors expresses its gratitude for Brennan's dedicated service to 5E over the last 13 months. Paul Weibel, currently serving as 5E's Chief Financial Officer, will assume the role of Chief Executive Officer effective immediately. Mr. Weibel has served as Chief Financial Officer since 2021, initially joining the Company's predecessor, American Pacific Borates Limited. The Company's Board has appointed Bryn Jones to the Board effective July 1, 2024. Barry Dick has previously been nominated to join the Company's Board, subject to election at the Company's upcoming Annual General Meeting scheduled for June 24, 2024. Joshua Malm, Interim Chief Accounting Officer since October 2023, has been appointed to Interim Chief Financial Officer with immediate effect. Rod MacLaine will serve as Vice President of Engineering and Construction, having joined the Company in May 2024. J.T. Starzecki, who has served as Chief Marketing Officer since joining the Company in August 2022, will transition to the role of Chief Strategy Officer. Effective June 11, 2024, Stefan Selig's six-month term as director will conclude, and effective June 30, 2024, Stephen Hunt will resign from the Board after seven years of services.

07:07 EDT 23andMe, Colorectal Cancer Alliance collaborate to advance research - 23andMe Holding and the Colorectal Cancer Alliance announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic Insights into Colorectal Cancer in the Black Community Study is part of 23andMe's continued efforts to raise awareness about important health conditions that touch many individuals but disproportionately impact the Black community. Through this study, 23andMe and the Alliance aim to recruit individuals who have African ancestry or identify as Black, African American, or of African descent who have been diagnosed with colorectal cancer, which includes colon cancer and cancer of the rectum.

07:06 EDT Intel launches Xeon 6 processors with E-cores, announces Gaudi pricing - At Computex, Intel unveiled "cutting-edge technologies and architectures poised to dramatically accelerate the AI ecosystem - from the data center, cloud and network to the edge and PC," the company announced. Intel launched Intel Xeon 6 processors with Efficient-cores, or "E-cores," that it says deliver "performance and power efficiency for high-density, scale-out workloads in the data center." Intel also announced pricing for Intel Gaudi 2 and Intel Gaudi 3 AI accelerator kits, that it says deliver "high performance with up to one-third lower cost compared to competitive platforms." Intel CEO Pat Gelsinger said: "The magic of silicon is once again enabling exponential advancements in computing that will push the boundaries of human potential and power the global economy for years to come. Intel is one of the only companies in the world innovating across the full spectrum of the AI market opportunity - from semiconductor manufacturing to PC, network, edge and data center systems. Our latest Xeon, Gaudi and Core Ultra platforms, combined with the power of our hardware and software ecosystem, are delivering the flexible, secure, sustainable and cost-effective solutions our customers need to maximize the immense opportunities ahead." Intel added: "Quickly building on these unmatched advantages, the company today revealed the architectural details of Lunar Lake - the flagship processor for the next generation of AI PCs. With a massive leap in graphics and AI processing power, and a focus on power-efficient compute performance for the thin-and-light segment, Lunar Lake will deliver up to 40% lower SoC power and more than 3 times the AI compute. It's expected to ship in the third quarter of 2024, in time for the holiday buying season." Reference Link

07:05 EDT Evolent Health to acquire AI management products and team from Machinify - Evolent Health has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a software platform that leverages advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its platform. Evolent and Machinify will also enter into a multi-year services agreement to support the success of the acquisition. The acquisition is subject to customary closing conditions. The solution to be acquired, Machinify Auth, functions as a co-pilot for nurses and doctors to reduce clinician workforce time by an average of 55% for complex, manual reviews for a large national payer customer and its provider network. Machinify is a privately held company based in Palo Alto, California. In addition, certain employees of Machinify will be re-badged as Evolent employees upon closing. Lastly, Machinify and Evolent expect to enter into a long-term services agreement at closing to support the development and integration of the platform with Evolent. The acquisition is immaterial to Evolent's revenue outlook and is estimated to be neutral to Adjusted EBITDA in the first year after closing. This transaction is anticipated to close in Q3.

07:04 EDT RumbleON names Tiffany Kice as CFO, effective June 24 - RumbleOn announced the appointment of Tiffany Kice as its new CFO, effective June 24. Kice brings over 25 years of experience in financial leadership roles for public and private companies across various industries, including extensive expertise in multi-site retail. Kice joins RumbleOn from Pegasus Logistics Group, a privately held logistics company where she served as CFO since 2020.

07:02 EDT Universal Stainless & Alloy set to join Russell 2000, 3000 Indexes - Universal Stainless & Alloy Products reported that it is set to join the broad-market Russell 2000 and 3000 Indexes at the conclusion of the annual reconstitution of the 2024 Russell US Indexes, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

07:00 EDT Creative Realities to be included in Russell Microcap Index - Creative Realities announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

06:54 EDT Pharvaris' deucrictibant shows positive results in HAE attack prevention - Pharvaris presented data highlighting the pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology, the 2024 Eastern Allergy Conference and the European Academy of Allergy and Clinical Immunology Congress 2024. In post-hoc analyses of the Phase 2 RAPIDe-1 clinical study data, resolution of HAE symptoms follow treatment with deucrictibant immediate-release capsule and placebo were measured. Treatment with a single dose of oral deucrictibant resulted in the majority of HAE attacks achieving substantial symptom resolution - 78.6% of participants with deucrictibant 20 mg vs. 22.4% of placebo within 24 hours. Evaluation of Treatment Satisfaction Questionnaire for Medication in participants in the Phase 2 CHAPTER-1 clinical study showed satisfaction with the effectiveness of deucrictibant is higher to placebo and is in-line with separate observations of high-efficacy injectables, while numerically more favorable than separate observations with other oral prophylactic therapies. The side effects and convenience subdomain scores were consistent between deucrictibant and placebo.

06:48 EDT Ferguson cuts FY24 CapEx view to ~$350M-$400M from ~$400M-$450M - Narrows FY24 adjusted operating margin view to 9.2%-9.6% from 9.2%-9.8%.

06:35 EDT Zomedica increases manufacturing capacity at Georgia facility - Zomedica completed the expansion of its global manufacturing and distribution facilities in Roswell, Georgia. The expansion, which increases the facility's total size to 18,400 sq. ft., adding 6,000 sq. ft. of adjacent space, enhances warehousing and sales order fulfillment efficiencies while increasing manufacturing capacity five-fold to support the growing demand for Zomedica's products.

06:33 EDT Carbon Revolution names Alia Comai as Chief Revenue Officer - Carbon Revolution is proud to announce the appointment of Alia Comai as Chief Revenue Officer, to lead the company's sales organization and continue developing global strategic partnerships. Comai brings over 25 years of extensive experience in the automotive sector, where she has held several pivotal leadership roles across product development, manufacturing, international business operations, program management, quality and sales. Before joining Carbon Revolution, Comai served as Vice President and General Manager - North America at Questar, where she was responsible for regional business growth and developed marketing strategies to promote the company, its products, and services, significantly driving partnerships and scale in the region.

06:31 EDT ESAB enters distribution agreement with INFRA Group in Mexico - ESAB has entered into a distribution agreement with INFRA Group to expand the availability of ESAB's differentiated solutions by offering its welding and gas control equipment to customers in Mexico. Founded in 1919, INFRA Group is a Mexican provider for industrial and medical gases, welding machines and a diverse range of welding products.

06:09 EDT Microsoft announces plans to invest SEK 33.7B in Swedish cloud, AI - Microsoft announces its largest single investment in Sweden, with plans to invest SEK 33.7B over two years on cloud infrastructure and artificial intelligence. The investment also includes an investment in raising the AI competence of 250,000 people. The initiative aims to accelerate Sweden's introduction of AI, increase the country's long-term competitiveness through skill development of current and future workforce, and create long-term benefits for the Swedish economy. Microsoft will expand its cloud and AI infrastructure and deploy 20,000 of the most advanced GPUs to its existing data center regions in Sandviken, Gavle and Staffanstorp. "Microsoft gives individuals, companies and society at large the opportunity to increase the power of innovation and democratize the use of AI through skill development, knowledge sharing and access to the latest technology and digital infrastructure. We want Sweden to be a global leader in innovation and technology to accelerate economic growth," Sophia Wikander, CEO of Microsoft Sweden, said.

06:06 EDT Ensign Group acquires skilled nursing facility in Arizona - Ensign Group acquired the real estate and operations of Wellsprings of Gilbert, a 32-bed skilled nursing facility located in Gilbert, Arizona. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Ensign's captive real estate company, and the acquisition was effective as of June 1. In a separate transaction on the same day, Ensign acquired the operations at The Springs at St. Andrews Village, a 58-bed skilled nursing facility located in Aurora, Colorado. This new facility will be operated by an Ensign affiliated operator. These acquisitions bring Ensign's growing portfolio to 312 healthcare operations, 29 of which also include senior living operations, across fourteen states.

06:04 EDT Ensign Group adds skilled nursing facility in Colorado - Ensign Group acquired the operations of The Springs at St. Andrews Village, a 58-bed skilled nursing facility located in Aurora, Colorado. This acquisition was effective as of June 1, 2024 and is subject to a long-term, triple net lease. In a separate transaction on the same day, Ensign acquired the operations and real estate at Wellsprings of Gilbert, a 32-bed skilled nursing facility located in Gilbert, Arizona. The real estate in this transaction was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate company. This new facility will be operated by an Ensign affiliated operator. These acquisitions bring Ensign's growing portfolio to 312 healthcare operations, 29 of which also include senior living operations, across fourteen states.

05:57 EDT Microsoft, Hitachi announce generative AI collaboration - Hitachi and Microsoft announced a projected multi-billion dollar collaboration over the next three years, that will accelerate social innovation with generative AI. Through this strategic alliance, Hitachi will propel growth of the Lumada business, with a planned revenue of $18.9B in FY24, and will promote operational efficiency and productivity improvements for Hitachi Group's 270 thousand employees. Specifically, Hitachi will embed the Microsoft cloud, Azure Open AI Service, Dynamics 365, Copilot for Microsoft 365, and GitHub Copilot into Lumada solutions to provide solutions for the energy, mobility and other industries to deliver better outcomes for businesses and society. In addition, the two companies will promote joint projects to address pressing business needs such as bolstering cloud services, enhancing security, and mitigating the environmental footprint of data centers, which have become an increasing area of focus with the growing use of generative AI.

05:50 EDT Innate Pharma announces results from TELLOMAK study - Innate Pharma announced results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides, or MF. The results were presented at the ASCO 2024 annual meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients received a median of four prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatment with lacutamab resulted in meaningful antitumor activity, regardless of the KIR3DL2 baseline expression, and an overall favorable safety profile. The global objective response rate, or ORR, was 16.8% and 22.4%, including 2 complete responses and 16 partial responses. In patients expressing a baseline KIR3DL2 of 1%, the ORR was 20.8% and 29.2%. Median progression-free survival was 10.2 months for all MF patients and 12 months in the KIR3DL2 1% group. Time to response was one month.

05:37 EDT Sonoco Products implements further price increase for core board, paperboard - Sonoco announced it is implementing a further price increase as input costs have continued to rise beyond our initial estimation. "We have already successfully implemented a second increase in the Italian market and this will now be applied in the rest of Europe at EUR 25/ton, valid for all shipments after 1st July, 2024. The economic climate continues to be challenging making this action necessary to maintain supply to our valued customer base in Europe," said Nikolaj Thybo, VP sales and marketing paper Europe.

05:29 EDT Hon Hai Precision to build advanced computer center in Taiwan with Nvidia - Hon Hai Technology (HNHPF) announced that it plans to build an advanced computing center in Kaohsiung, Taiwan, with the Nvidia (NVDA) Blackwell platform at its core, as the CEOs of the two technology bellwethers reaffirmed their strong partnership at Computex 2024. The latest collaboration between Foxconn and Nvidia signals a deepening commitment by the world's largest electronics manufacturing service provider and market leader in making AI servers, alongside its world-class partner, to drive intelligent ecosystems covering AI, electric vehicles, smart factories, robotics, smart cities and other fields. Nvidia founder and CEO Jensen Huang and Foxconn chairman and CEO Young Liu caught up with each other on the exhibition floor of Computex, getting a tour about their cooperation at the booth set up by Ingrasys, the Foxconn subsidiary that has been at the manufacturing epicenter of Nvidia's GB200 NVL72, MGX, HGX and other innovative products. Following the tour, Huang noted that Nvidia and Foxconn have worked closely together on various product development, and the proof of the cooperation is clear, especially with the Blackwell product line-up. On the spot, Chairman Liu announced that Foxconn will join hands with Nvidia to build an advanced computing center in Kaohsiung with the Nvidia Blackwell platform at its core. The computing center, anchored by the superchip GB200 servers, consists of a total of 64 racks and 4,608 GPUs, is slated for completion by 2026. Nvidia AI technology will drive Foxconn's three smart platforms: Smart Manufacturing. Smart EV. Smart City. Both companies will continue to deepen cooperation in AI, electric vehicles, smart factories, robots, smart cities and other fields, and demonstrate the strong competitiveness brought by AI through Foxconn's huge manufacturing scale.

05:19 EDT NXP Semiconductors collaborates with ZF Friedrichshafen on EV solutions - NXP Semiconductors announced a collaboration with ZF Friedrichshafen AG on next-generation SiC-based traction inverter solutions for electric vehicles, or EVs. By leveraging NXP's advanced GD316x high-voltage, or HV, isolated gate drivers, the solutions are designed to accelerate the adoption of 800-V and SiC power devices. Safe, efficient and higher performance traction inverters enabled by the GD316x product family can be designed to extend EV range and reduce the number of charging stops while lowering system level costs for OEMs. The collaboration between ZF and NXP is a step towards accelerating the electrification of the automotive industry, and creating more safe, sustainable, and energy-efficient EVs for the future.

05:10 EDT MicroAlgo, WiMi jointly establish micro-consciousness quantum research center - MicroAlgo (MLGO) announced that the company and WiMi (WIMI) will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, polymer chemistry, philosophy, psychology, sociology, and many other disciplines to form a comprehensive research institute based on various disciplines centered on consciousness. Research in basic science is a long process that requires a long-term commitment from scientists. At the same time, it also requires the support and promotion from the society and enterprises. Against the backdrop, MicroAlgo and WiMi plan to establish a micro-consciousness quantum research center together, aiming to utilize the characteristics of quantum theory, combined with the artificial intelligence technology, to study the relationship between consciousness and quantum.

05:02 EDT Cambium Networks enters collaboration with Nonius - Cambium Networks announced its collaboration with Nonius, a global company offering digital technology for hotel guests. This strategic partnership leverages Cambium Networks' advanced hospitality solutions which include Wi-Fi access points, comprehensive switching solutions, and cnMaestro cloud management platform to meet the evolving connectivity demands of hotel guests, showcased by the successful implementation at Dakota Hotels in the United Kingdom, ensuring a seamless digital experience that complements the luxury and comfort Dakota Hotels is known for.